Medicare Enrolled
Dr. Chirag Shah, MD
Internal Medicine · Toms River, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Chirag Shah is an internal medicine specialist in Toms River, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Shah performed 236,816 Medicare services across 2,919 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shah received a total of $9,362 from 73 pharmaceutical and/or device companies across 308 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in NJ
$9,362 industry payments
Medicare Practice Summary
Medicare Utilization ↗236,816
Medicare services
Top 0% in NJ for internal medicine
2,919
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~11,841 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
69,001 | $1 | $2 |
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
48,660 | $0 | $1 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
36,180 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 25,680 | $18 | $35 |
| Anti-nausea injection (aprepitant) | 11,960 | $1 | $3 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
10,040 | $6 | $15 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,350 | $0 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 6,834 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
6,142 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,560 | $6 | $15 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,186 | $26 | $100 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
1,128 | $106 | $375 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,049 | $103 | $250 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
956 | $72 | $175 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
850 | $12 | $50 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
729 | $67 | $150 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
532 | $116 | $250 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
424 | $2 | $100 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
401 | $64 | $150 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
360 | $42 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
291 | $57 | $150 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
260 | $111 | $250 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
246 | $58 | $200 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
218 | $1 | $2 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
217 | $25 | $150 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
196 | $11 | $60 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
162 | $1 | $10 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
147 | $21 | $150 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
137 | $14 | $60 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
134 | $18 | $50 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
118 | $133 | $250 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
110 | $49 | $120 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
86 | $30 | $100 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
70 | $2 | $5 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
69 | $3 | $7 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
54 | $18 | $50 |
| New patient office visit, complex (60-74 min) | 50 | $181 | $250 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
44 | $148 | $300 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
42 | $144 | $250 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
38 | $1 | $5 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
37 | $27 | $150 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
21 | $98 | $200 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
21 | $101 | $150 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
13 | $72 | $85 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
13 | $29 | $30 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.2% high complexity
68.1% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,362
Total received (2018-2024)
Avg $1,337/year across 7 years
Top 8% in NJ for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
73
Companies
308
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,297 (77.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,777 (19.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$288 (3.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,043
2023
$937
2022
$722
2021
$1,636
2020
$821
2019
$1,406
2018
$2,798
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$147
Becton, Dickinson and Company
$121
BeiGene USA, Inc.
$98
TAIHO ONCOLOGY, INC.
$96
Janssen Biotech, Inc.
$77
PFIZER INC.
$70
E.R. Squibb & Sons, L.L.C.
$63
Novartis Pharmaceuticals Corporation
$58
Daiichi Sankyo Inc.
$50
ARRAY BIOPHARMA INC
$34
GlaxoSmithKline, LLC.
$33
PUMA BIOTECHNOLOGY, INC.
$31
Genentech USA, Inc.
$31
Tempus AI, Inc
$19
Gilead Sciences, Inc.
$18
Merck Sharp & Dohme LLC
$17
Eisai Inc.
$17
Celgene Corporation
$16
Coherus Biosciences Inc.
$16
JAZZ PHARMACEUTICALS INC.
$16
Ipsen Biopharmaceuticals, Inc
$16
Top 3 companies account for 35.0% of 2024 payments
All-time payments by company (2018-2024) ›
Puma Biotechnology, Inc.
$1,154
Partner Therapeutics, Inc.
$653
Janssen Biotech, Inc.
$570
E.R. Squibb & Sons, L.L.C.
$522
PFIZER INC.
$447
Amgen Inc.
$440
ASD SPECIALTY HEALTHCARE, LLC
$384
Novartis Pharmaceuticals Corporation
$345
Genentech USA, Inc.
$308
Regeneron Healthcare Solutions, Inc.
$276
AstraZeneca Pharmaceuticals LP
$252
Impulse Dynamics (USA) Inc.
$247
Seagen Inc.
$232
ASD Specialty Healthcare, LLC
$178
Celgene Corporation
$161
Coherus Biosciences Inc.
$141
GENZYME CORPORATION
$138
Heron Therapeutics, Inc.
$133
Pharmacyclics LLC, An AbbVie Company
$129
Pharmacyclics LLC, an AbbVie Company
$128
Silk Road Medical, Inc.
$122
Becton, Dickinson and Company
$121
TISSUETECH, INC.
$121
Astellas Pharma US Inc
$118
Epizyme, Inc.,
$117
Verastem, Inc.
$114
Boehringer Ingelheim Pharmaceuticals, Inc.
$100
BeiGene USA, Inc.
$98
TAIHO ONCOLOGY, INC.
$96
Merck Sharp & Dohme Corporation
$94
TissueTech, Inc.
$89
Merck Sharp & Dohme LLC
$70
Gilead Sciences, Inc.
$70
Exelixis Inc.
$70
Lilly USA, LLC
$69
Daiichi Sankyo Inc.
$64
Dompe US, Inc.
$64
ARRAY BIOPHARMA INC
$59
GlaxoSmithKline, LLC.
$59
SUN PHARMACEUTICAL INDUSTRIES INC.
$54
Incyte Corporation
$52
SANOFI-AVENTIS U.S. LLC
$45
Octapharma USA, Inc.
$44
ABBVIE INC.
$42
JAZZ PHARMACEUTICALS INC.
$42
Roche Diagnostics Corporation
$35
Pharmacosmos Therapeutics Inc.
$32
PUMA BIOTECHNOLOGY, INC.
$31
Eisai Inc.
$30
Dendreon Pharmaceuticals LLC
$29
Janssen Scientific Affairs, LLC
$25
G1 Therapeutics, Inc.
$25
AMAG Pharmaceuticals, Inc.
$24
AbbVie Inc.
$24
Seattle Genetics, Inc.
$20
Tempus AI, Inc
$19
Ipsen Biopharmaceuticals, Inc
$16
SERVIER PHARMACEUTICALS LLC
$15
Takeda Pharmaceuticals U.S.A., Inc.
$15
Alexion Pharmaceuticals, Inc.
$15
Servier Pharmaceuticals LLC
$14
Otsuka America Pharmaceutical, Inc.
$14
PORTOLA PHARMACEUTICALS, INC.
$14
Helsinn Therapeutics (U.S.), Inc.
$14
Grifols USA, LLC
$14
EISAI INC.
$14
Medtronic, Inc.
$14
AbbVie, Inc.
$14
TOLMAR Pharmaceuticals, Inc.
$14
Karyopharm Therapeutics Inc.
$14
Bayer HealthCare Pharmaceuticals Inc.
$14
Global Blood Therapeutics, Inc.
$13
Aveo Pharmaceuticals, Inc.
$11
Top 3 companies account for 25.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · Abraxane · Alecensa · Avastin · BEVYXXA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CALQUENCE · CINVANTI · COSELA · Cabometyx · Cequa · Columvi · Copiktra · DARZALEX · DIS Navify Software · ELIGARD · ELITEK · ENROUTE Transcarotid Stent · EPKINLY · ERBITUX · ERLEADA · Enhertu · Erivedge · Erleada · FERAHEME · FOTIVDA · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JARDIANCE · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUPRON DEPOT · Lenvima · Leukine · Lupron · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · ONUREG · OPDIVO · OPDUALAG · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · OXERVATE · Onivyde · Optimizer Smart System · PADCEV · PANZYGA · PIQRAY · PROKERA · PROMACTA · PROVENGE · Phasix Mesh · Pomalyst · Prokera · Prolia · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · SANDOSTATIN · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · Stivarga · Sustol · TAFINLAR · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · Trodelvy · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · Venclexta · XALATAN · XALKORI · XGEVA · XPOVIO · XT CDX · XTANDI · Xembify · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (78%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 8% for internal medicine in NJ.
Geographic Context
Internal medicine physicians within 10 mi
584
Per 100K population
90.3
County median income
$86,411
Nearest hospital
COMMUNITY MEDICAL CENTER
4.3 mi
4.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shah is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ), with low-engagement industry engagement in the top 8% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Shah performed 69,001 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $9,362 from 73 companies across 308 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other internal medicine physicians in Toms River?
Dr. Shah's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Toms River
Browse internal medicine physicians in Toms River ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in NJ
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in NJ
Which NJ internal medicine physicians receive the most from drug and device companies.
By company
Puma Biotechnology, Inc. Payments to Doctors
See all physicians who received payments from Puma Biotechnology, Inc.
By company
Partner Therapeutics, Inc. Payments to Doctors
See all physicians who received payments from Partner Therapeutics, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology